Article
Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues.
Lung cancer (Amsterdam, Netherlands) - 1 Apr 2011
Gridelli C, De Marinis F, Di Maio M, Cortinovis D, Cappuzzo F, Mok T
Abstract excerpt
Randomized trials comparing gefitinib with chemotherapy as first-line treatment in patients with EGFR mutated advanced NSCLC support gefitinib as a new, highly effective treatment option in this setting. However, its use in clinical practice has several relevant implications and open issues. In o...
Topics
- Antineoplastic Agents
- Carcinoma, Non-Small-Cell Lung
- Clinical Trials as Topic
- ErbB Receptors
- Gefitinib
- Humans
- Lung Neoplasms
- Mutation
- Neoplasm Staging
- Quinazolines